By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company AstraZeneca PLC

AstraZeneca PLC (AZN)

NASDAQ Currency in USD
$81.10
+$0.29
+0.36%
Last Update: 11 Sept 2025, 20:00
$251.40B
Market Cap
29.38
P/E Ratio (TTM)
1.27%
Forward Dividend Yield
$61.24 - $82.41
52 Week Range

AZN Stock Price Chart

Explore AstraZeneca PLC interactive price chart. Choose custom timeframes to analyze AZN price movements and trends.

AZN Company Profile

Discover essential business fundamentals and corporate details for AstraZeneca PLC (AZN) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Drug Manufacturers - General

IPO Date

12 May 1993

Employees

94.30K

CEO

Pascal Claude Roland Soriot

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Financial Timeline

Browse a chronological timeline of AstraZeneca PLC corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 27 Apr 2026

Upcoming earnings on 4 Feb 2026

Upcoming earnings on 11 Nov 2025

EPS estimate is $1.13.

Earnings released on 29 Jul 2025

EPS came in at $1.09 matching the estimated $1.09, while revenue for the quarter reached $14.46B , missing expectations by -1.99%.

Dividend declared on 29 Jul 2025

A dividend of $0.52 per share was announced, adjusted to $0.52. The dividend was paid on 8 Sept 2025.

Earnings released on 29 Apr 2025

EPS came in at $1.24 surpassing the estimated $1.10 by +12.73%, while revenue for the quarter reached $13.59B , missing expectations by -3.34%.

Earnings released on 6 Feb 2025

EPS came in at $1.05 falling short of the estimated $1.07 by -1.87%, while revenue for the quarter reached $14.89B , beating expectations by +11.60%.

Dividend declared on 6 Feb 2025

A dividend of $1.05 per share was announced, adjusted to $1.05. The dividend was paid on 24 Mar 2025.

Earnings released on 12 Nov 2024

EPS came in at $1.04 surpassing the estimated $1.03 by +0.97%, while revenue for the quarter reached $13.57B , beating expectations by +3.65%.

Earnings released on 25 Jul 2024

EPS came in at $0.99 falling short of the estimated $1.20 by -17.50%, while revenue for the quarter reached $12.94B , missing expectations by -1.09%.

Dividend declared on 25 Jul 2024

A dividend of $0.49 per share was announced, adjusted to $0.49. The dividend was paid on 9 Sept 2024.

Earnings released on 25 Apr 2024

EPS came in at $1.03 falling short of the estimated $1.22 by -15.57%, while revenue for the quarter reached $12.68B , beating expectations by +7.47%.

Earnings released on 8 Feb 2024

EPS came in at $0.73 falling short of the estimated $0.79 by -7.59%, while revenue for the quarter reached $12.02B , missing expectations by -0.46%.

Dividend declared on 8 Feb 2024

A dividend of $0.99 per share was announced, adjusted to $0.99. The dividend was paid on 25 Mar 2024.

Earnings released on 9 Nov 2023

EPS came in at $0.87 surpassing the estimated $0.85 by +2.35%, while revenue for the quarter reached $11.49B , missing expectations by -0.52%.

Earnings released on 28 Jul 2023

EPS came in at $1.08 surpassing the estimated $0.95 by +13.68%, while revenue for the quarter reached $11.42B , beating expectations by +3.67%.

Dividend declared on 28 Jul 2023

A dividend of $0.47 per share was announced, adjusted to $0.47. The dividend was paid on 11 Sept 2023.

Earnings released on 27 Apr 2023

EPS came in at $0.96 falling short of the estimated $1.07 by -10.28%, while revenue for the quarter reached $10.88B , beating expectations by +2.59%.

Earnings released on 9 Feb 2023

EPS came in at $0.69 surpassing the estimated $0.67 by +2.99%, while revenue for the quarter reached $11.21B , missing expectations by -0.38%.

Dividend declared on 9 Feb 2023

A dividend of $0.97 per share was announced, adjusted to $0.99. The dividend was paid on 27 Mar 2023.

Earnings released on 10 Nov 2022

EPS came in at $0.84 surpassing the estimated $0.72 by +16.67%, while revenue for the quarter reached $10.98B , beating expectations by +1.79%.

Dividend declared on 1 Aug 2022

A dividend of $0.46 per share was announced, adjusted to $0.47. The dividend was paid on 12 Sept 2022.

Earnings released on 29 Jul 2022

EPS came in at $0.86 surpassing the estimated $0.78 by +10.26%, while revenue for the quarter reached $10.77B , beating expectations by +3.03%.

Earnings released on 29 Apr 2022

EPS came in at $0.95 surpassing the estimated $0.86 by +10.47%, while revenue for the quarter reached $11.39B , beating expectations by +3.63%.

Earnings released on 10 Feb 2022

EPS came in at $0.84 surpassing the estimated $0.77 by +9.09%, while revenue for the quarter reached $12.01B , beating expectations by +7.66%.

Dividend declared on 10 Feb 2022

A dividend of $0.97 per share was announced, adjusted to $0.99. The dividend was paid on 28 Mar 2022.

Earnings released on 12 Nov 2021

EPS came in at $0.54 falling short of the estimated $0.63 by -14.29%, while revenue for the quarter reached $9.87B , missing expectations by -12.50%.

Dividend declared on 30 Jul 2021

A dividend of $0.44 per share was announced, adjusted to $0.45. The dividend was paid on 13 Sept 2021.

Earnings released on 29 Jul 2021

EPS came in at $0.45 surpassing the estimated $0.43 by +4.65%, while revenue for the quarter reached $8.22B , beating expectations by +8.36%.

Earnings released on 30 Apr 2021

EPS came in at $0.81 surpassing the estimated $0.71 by +14.08%, while revenue for the quarter reached $7.32B , beating expectations by +10.29%.

Dividend declared on 12 Feb 2021

A dividend of $0.95 per share was announced, adjusted to $0.95. The dividend was paid on 29 Mar 2021.

Earnings released on 11 Feb 2021

EPS came in at $0.54 surpassing the estimated $0.53 by +1.89%, while revenue for the quarter reached $7.41B , missing expectations by -17.07%.

Earnings released on 5 Nov 2020

EPS came in at $0.47 surpassing the estimated $0.44 by +6.82%, while revenue for the quarter reached $6.58B , beating expectations by +7.32%.

AZN Stock Performance

Access detailed AZN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run